Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy

NCT07372079 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Neoadjuvant Therapy
Immune Checkpoint Inhibitors
QL1706

Interventions

DRUG: QL1706 combined with Chemotherapy

Sponsor

Tianjin Medical University Cancer Institute and Hospital